Patents Examined by Sang-ming Hui
  • Patent number: 9156824
    Abstract: The present invention provides isoindolinone compounds, or a pharmaceutically acceptable salt thereof, that inhibit CDC7 and, therefore may be useful in treating cancer.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: October 13, 2015
    Assignee: Eli Lilly and Company
    Inventors: Robert Dean Dally, Timothy Andrew Woods
  • Patent number: 7771733
    Abstract: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: August 10, 2010
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Eugene H. Gans, Mitchell S. Wortzman
  • Patent number: RE41491
    Abstract: This invention discloses (20S)-1?-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat immune disorders in humans as well as renal osteodystrophy.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: August 10, 2010
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame